Do we need to do fluorescence in situ hybridization analysis in myelodysplastic syndromes as often as we do?

[1]  L. Arenillas,et al.  Fluorescence in situ hybridization improves the detection of 5q31 deletion in myelodysplastic syndromes without cytogenetic evidence of 5q- , 2008, Haematologica.

[2]  D. Haase.  Cytogenetic features in myelodysplastic syndromes , 2008, Annals of Hematology.

[3]  Thomas H Müller,et al.  New insights into the prognostic impact of the karyotype in MDS and correlation with subtypes: evidence from a core dataset of 2124 patients. , 2007, Blood.

[4]  P. N. Rao,et al.  Guidance for fluorescence in situ hybridization testing in hematologic disorders. , 2007, The Journal of molecular diagnostics : JMD.

[5]  A. Giagounidis,et al.  Lenalidomide in the context of complex karyotype or interrupted treatment: case reviews of del(5q)MDS patients with unexpected responses , 2006, Annals of Hematology.

[6]  A. Tefferi,et al.  Efficacy of conventional cytogenetics and FISH for EGR1 to detect deletion 5q in hematological disorders and to assess response to treatment with Lenalidomide. , 2006, Leukemia research.

[7]  P. Greenberg,et al.  Lenalidomide in the myelodysplastic syndrome with chromosome 5q deletion. , 2006, The New England journal of medicine.

[8]  A. Bagg,et al.  The genetics of the myelodysplastic syndromes: Classical cytogenetics and recent molecular insights , 2006, Hematology.

[9]  H. Özdoğu,et al.  Conventional and molecular cytogenetic findings of myelodysplastic syndrome patients , 2005, Clinical and Experimental Medicine.

[10]  L. Rimsza,et al.  Efficacy of lenalidomide in myelodysplastic syndromes. , 2005, The New England journal of medicine.

[11]  D. Neuberg,et al.  Comparison of interphase FISH and metaphase cytogenetics to study myelodysplastic syndrome: an Eastern Cooperative Oncology Group (ECOG) study. , 2003, Leukemia research.

[12]  C. Klersy,et al.  Is FISH a relevant prognostic tool in myelodysplastic syndromes with a normal chromosome pattern on conventional cytogenetics? A study on 57 patients , 2003, Leukemia.

[13]  M. Silva,et al.  Comparison of cytogenetics with FISH in 40 myelodysplastic syndrome patients. , 2002, Leukemia research.

[14]  G. Dewald,et al.  Primary myelodysplastic syndrome with normal cytogenetics: utility of 'FISH panel testing' and M-FISH. , 2002, Leukemia research.

[15]  A. Cuneo,et al.  Clinical importance of interphase cytogenetics detecting occult chromosome lesions in myelodysplastic syndromes with normal karyotype , 2001, Leukemia.

[16]  S. Schwartz,et al.  A multicenter investigation with interphase fluorescence in situ hybridization using X- and Y-chromosome probes. , 1998, American journal of medical genetics.

[17]  T Hamblin,et al.  International scoring system for evaluating prognosis in myelodysplastic syndromes. , 1997, Blood.

[18]  L. Shaffer,et al.  Comprar ISCN 2009 - An International System for Human Cytogenetic Nomenclature | Marilyn L. Slovak | 9783805589857 | Karger AG , 2009 .

[19]  E. Thorland,et al.  Preclinical validation of fluorescence in situ hybridization assays for clinical practice , 2006, Genetics in Medicine.

[20]  J. Cigudosa,et al.  Identification of novel cytogenetic markers with prognostic significance in a series of 968 patients with primary myelodysplastic syndromes. , 2005, Haematologica.

[21]  M. Mancini,et al.  Detection and monitoring of trisomy 8 by fluorescence in situ hybridization in acute myeloid leukemia: a multicentric study. , 1998, Haematologica.

[22]  L. Nagarajan.  Molecular analysis of the 5q- chromosome. , 1995, Leukemia & lymphoma.

[23]  Iscn.  International System for Human Cytogenetic Nomenclature , 1978 .